Carcinoembryonic antigen (CEA) as tumor marker in lung cancer

Lung Cancer

Volumn 76, Issue 2, 2012, Pages 138-143

  Grunnet, M ^a   Sorensen, J B ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Biomarker; Carcinoembryonic antigen (CEA); Lung cancer; NSCLC; Prognostic significance; Tumor marker index

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19;

ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; DISEASE MARKER; HUMAN; LUNG CANCER; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDLINE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

CARCINOEMBRYONIC ANTIGEN; HUMANS; LUNG NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859435256     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.11.012     Document Type: Review

References (39)

1. GLOBECAN 2008. http://www.iarc.fr/en/publications/index.php.
2. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
3. Thomas S.N., Zhu F., Schnaar R.L., Alves C.S., Konstantopoulos K. Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem 2008, 283(June (23)):15647-15655.
4. Konstantopoulos K., Thomas S.N. Cancer cells in transit: the vascular interactions of tumor cells. Annu Rev Biomed Eng 2009, 11:177-202.
5. Thomas S.N., Tong Z., Stebe K.J., Konstantopoulos K. Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics. Biorheology 2009, 46(3):207-225.
6. Tufman A., Huber M. Biological markers in lung cancer: a clinician's perspective. Cancer Biomark 2010, 6. [Number 3-4/2009/2010].
7. Schneider J., Philipp M., Velcovsky H.-G., Morr H., Katz N. Pro-Gastrin-Releasing Peptide (ProGRP). Neuron specific enolase and cytokeratin 19-fragments (CYFRA21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res 2003, 23:885-894.
8. Oremek G.M., Sauer-Eppel H., Bruzdziak T.H. Value of tumour and inflammatory markers in lung cancer. Anticancer Res 2007, 27:1911-1916.
9. Hatzakis K.D., Froudarakis M.E., Bouros D., Tzanakis N., Karkavitsas N., Siafakas N.M. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002, 69:25-29.
10. Ford C.H.J., Stokes H.J., Newman C.E. Carcinoembryonic antigen and prognosis after radical surgery for lung cancer: immunhistochemical localization and serum levels. Br J Cancer 1981, 44:145.
11. Arrieta O., Saaveda-Perez D., Kuri R., Aviles-Salas A., Martinez L., Mendoza-Posada D., et al. Brain metastasis development and poor survival associated with CEA level in advanced non-small cell lung cancer: a prospective study. BMC Cancer 2009, 9:119.
12. Tomita M., Shimizu T., Matsuzaki Y., Hara M., Ayabe T., Onitsuka T., et al. Prognostic significance carcinoembryonic antigen level in pleural lavage fluid for patients with lung adenocarcinoma. Ann Thorac Surg 2005, 80:276-281. 2005.
13. Schneider J., Philipp M., Velcovsky H.-G., Morr, Katz N., Neu K., et al. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA21-1. NSE & SCC in the diagnosis of lung cancer. Anticancer Res 2000, 20:5053-5058.
14. Zaleska M., Szturmowicz M., Zych J., Sliz B., Demkow U., Langfort R., et al. Elevated serum NSE in inoperable non-small-cell lung carcinoma (NSCLC) is associated with a better response but worse prognosis. Pneumonol Alergol Pol 2010, 78(1):14-20.
15. Okada M., Sakamoto T., Nishio W., Uchino K., Tsubota N. Characteristics and prognosis of patients after resection of NSCLC measuring 2cm or less in greatest dimension. Cancer 2003, 98(3):535-543.
16. Rubins J.B., Dunitz J., Rubins H.B., Maddaus M.A., Niewoehner D.E. Serum CEA as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 1998, 116(3):412-416.
17. Matsuoka K., Sumitomo S., Nakashima N., Mikasi N. Prognostic value of CEA and CYFRA21-1 in patients with pathological stage I NSCLC. Eur J Cardio-Thorac Surg 2007, 32:435-439.
18. Hotta K., Segwa Y., Takigawa N., Kishino D., Saeki H., Nakata M., et al. Evaluation of the relationship between serum CEA level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer. Anticancer Res 2000, 20(3B):2177-2180.
19. Icard P., Regnard J.F., Essomba A., Panebianco V., Levasseur P., Magdelleinat P. Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. Ann Thorac Surg 1994, 58:811-814.
20. Muley T., Dienemann H., Ebert W. CYFRA21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res 2004, 24:1953-1956.
21. Nisman B., Amir G., Lafair J., Heching N., Lyass O., Peretz T., et al. Prognostic value of CYFRA21-1. TPS and CEA in different histologic types NSCLC. Anticancer Res 1999, 19(4c):3549-3552.
22. Tomita M., Matsuzali Y., Edgawa M., shimizu, Hara M., Onitsuka T. Prognostic significance of preoperative CEA level in lung adenocarcinoma but not squamous cell carcinoma. Thorac Cardiovasc Surg 2004, 10:76-80.
23. Iwasaki A., Shirakusa T., Yasuteru Y., Enatsu S., Yamamoto M. Evaluation of the treatment of NSCLC with brain metastasis and the role of risk score as a survival predictor. Eur J Cardio-Thorac Surg 2004, 26:488-493.
24. Tomita M., Shimizu T., ayabe T., Yonei A., Onitsuka T. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA21-1 in NSCLC. Anticancer Res 2010, 30:3099-3102.
25. Tomita M., Shimizu T., ayabe T., Yonei A., Onitsuka T. Serum CEA level in NSCLC patients with normal preoperative serum levels. J Thorac Cardiovasc Surg 2009, 57:303-306.
26. Suzuki K., Nagai K., Yohida J., Moriyama E., Nishimura M., Takahashi K., et al. Prognostic factors in clinical stage I NSCLC. Ann Thorac Surg 1999, 67:927-932.
27. Sawabata N., Ohta M., Takeda S.-I., Hirano H., Okumura Y., Asada H., et al. Serum CEA level in surgically resected clinical stage I patients with NSCLC. Ann Thorac Surg 2002, 74:174-179.
28. Kulpa J., Wojcik E., Reinfuss M., Kolodziejski L. CEA, SCC, CYFRA21-1 and NSE in squamous cell lung cancer. Clin Chem 2002, 48(11):1931-1937.
29. Nisman B., Lafair J., Heching N., Olga L., Baras M., Peretz T., et al. Evaluation of tissue polypeptide antigen. CYFRA21-1 and CEA in NSCLC. Cancer 1998, 82:1850-1859.
30. Blankenburg F., Hatz R., Nagel D., Ankerst D., Reinmiedl J., Gruber C., et al. Preoperative CYFRA21-1 and CEA as prognostic factors in patients with stage I NSCLC. Tumor Biol 2008, 29:272-277.
31. Buccheri G., Ferrigno D., Vola F. CEA TPA and other prognostic indicators in squamous cell lung cancer. Lung Cancer 1993, 10:21-33.
32. Reinmut N., Brandt B., Semik M., Kunze W.P., Achatzy R., Scheld H., et al. Prognostic impact of CYFRA21-1 and other serum markers in completely resected non-small-cell lung cancer. Lung Cancer 2002, 36:265-270.
33. Kobayashi N., Toyooka S., Soh J., Ichimura K., Yanai H., Suehisa H., et al. Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20mm or less. J Thorac Oncol 2007, 2:808-812.
34. Diez M., Torres A., Maestro M.L.M.L., Ortega M.D., Gomez A., Pollan M., et al. Prediction of survival and recurrence by serum and cytosolic levels of CEA. CA-125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer 1996, 73:1248-1254.
35. Kashiwabara, Saeki, Sasaki Combined elevation of postoperative serum levels of CEA less than or equal to 2.5ng/ml and absence of vascular invasion may predict no recurrence of stage I adenocarcinoma lung cancer. J Thorac Oncol 2008, 3(12):1416-1420.
36. Buccheri G., Ferringo D. Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test. Ann Thorac Surg 2003, 75:973-980.
37. Sakao Y., Tomimitsu S., Takeda Y., Natsuaki M., Itoh T. Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early stage lung adenocarcinoma. Eur J Cardio-Thorac Surg 2004, 25:520-522.
38. Kao C.H., Hsieh J.F., Ding H.J. Cytokeratin fragment 19 (CYFRA21-1) and carcino-embryonic antigen for early prediction of recurrence of lung adenocarcinoma. Lung 1999, 177:333-337.
39. Vilmar A.C., Sorensen J.B. Customizing chemotherapy in advanced non-small cell lung cancer: daily practice and perspectives. Eur Respir Rev 2011, 20:45-52.